

Edgar Filing: NOVADEL PHARMA INC - Form NT 10-Q

NOVADEL PHARMA INC  
Form NT 10-Q  
June 12, 2003

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 12b-25

Commission File Number-000-23399

NOTIFICATION OF LATE FILING

(Check one)                      Form 10-K and Form 10-KSB  
-----  
                                    Form 20-F  
-----  
                                    Form 11-K  
-----  
                                    X Form 10-Q and Form 10-QSB  
-----  
                                    Form N-SAR  
-----

For Period Ended April 30, 2003  
\_\_\_ Transition Report on Form 10-K and Form 10-KSB  
\_\_\_ Transition Report on Form 20-F  
\_\_\_ Transition Report on Form 11-K  
\_\_\_ Transition Report on Form 10-Q and Form 10-QSB  
\_\_\_ Transition Report on Form N-SAR  
For the Transition Period Ended:\_\_\_\_\_

Read Instructions (on back page) Before Preparing Form.  
Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:  
-----

-----  
PART I--REGISTRANT INFORMATION

Full Name of Registrant: NOVADEL PHARMA INC.  
-----

Former Name of Registrant:  
-----

Address of Principal Executive Office (Street and Number):

31 State Highway 12, Flemington, NJ 08822  
-----

Edgar Filing: NOVADEL PHARMA INC - Form NT 10-Q

PART II--RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25b, the following should be completed. (Check box if appropriate):

- (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
- (b) The subject annual report, semi-annual report, transition report on Forms 10-K, 10-KSB, Form 20-F, 11-K, Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Forms 10-Q, 10-QSB, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III--NARRATIVE

State below in reasonable detail the reasons why the Forms 10-K, 10-KSB, 20-F, 11-K, 10-Q,10-QSB, N-SAR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach Extra Sheets if Needed)

The Company has not been able to compile the requisite financial data and other narrative information necessary to enable it to have sufficient time to complete the Company's Quarterly Report on Form 10-QSB by the required filing date, without unreasonable effort and expense.

PART IV--OTHER INFORMATION

- (1) Name and telephone number of person to contact in regard to this notification

Gary Shangold ----- (Name)	(908) ----- (Area Code)	782-3431 ----- (Telephone Number)
----------------------------------	-------------------------------	---

- (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) been filed? If answer is no, identify report(s). X Yes No

- (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes      X      No  
 ---      ----

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Edgar Filing: NOVADEL PHARMA INC - Form NT 10-Q

NOVADEL PHARMA INC.  
(Name of Registrant as Specified In Charter)

has caused this notification to be signed on its behalf by the undersigned hereto duly authorized

Dated: June 12, 2003

NOVADEL PHARMA INC.

By: /s/ Gary Shangold, M.D.

-----  
Gary Shangold, M.D., President and  
Chief Executive Officer

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.

ATTENTION

Intention misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

GENERAL INSTRUCTIONS

1. This form is required by Rule 12b-25 (17 CFR 240.12b-25) of the General Rules and Regulations under the Securities Exchange Act of 1934.
2. One signed original and four conformed copies of this form and amendments thereto must be completed and filed with the Securities and Exchange Commission, Washington, D.C. 20549, in accordance with Rule 0-3 of the General Rules and Regulations under the Act. The information contained in or filed with the form will be made a matter of public record in the Commission files.
3. A manually signed copy of the form and amendments thereto shall be filed with each national securities exchange on which any class of securities of the registrant is registered.
4. Amendments to the notifications must also be filed on form 12b-25 but need not restate information that has been correctly furnished. The form shall be clearly identified as an amendment notification.